Method and system for exposing hidden or masked antigenic sites of viral specimens present in biosamples using a home-based COVID-19 rapid lateral flow immunoassay test
A disease detection system including a platform or cartridge to perform testing using a rapid lateral flow chromatographic immunoassay (LFIA) test intended for the qualitative detection of the disease in a sample, such as collected sputum, disrupted by a digestive enzyme and a detergent to release its content and digest its proteins and other polymeric molecules. A method of the present invention includes treating a sample with a digestive enzyme and a detergent to disrupt the collected sample releasing content and digesting proteins of the sample to form a lysed-digested-extracted sample, applying the lysed-digested-extracted sample to a platform or cartridge, performing a rapid lateral flow chromatographic immunoassay (LFIA) test of the lysed-digested-extracted sample using the platform or cartridge and detecting presence or absence of an analyte of interest from the tested lysed-digested-extracted sample.
1. A disease detection system, comprising:
a platform or cartridge configured to perform a rapid lateral flow chromatographic immunoassay (LFIA) test;
a container or tube configured for receiving a sample;
a detergent contained in the container or tube, the detergent comprising one or more non-ionic detergents;
a digestive enzyme, the digestive enzyme is in solution with the detergent contained in the container or tube or the digestive enzyme is immobilized on a solid support, the solid support being a surface of a particle within the container or tube or the solid support being an inner surface of the container or tube, the digestive enzyme is one or more of subtilisin, trypsin, pepsin, chymotrypsin, pronase, papain, proteinase K, thermophilic enzyme, hyaluronidase, and amylase;
a sample application zone disposed on or in the platform or cartridge configured for receiving the sample, the sample having been disrupted by the digestive enzyme and the detergent contained in the container or tube to release content and digest proteins and glycoproteins of the sample to form a lysed-digested-extracted sample; and
a migration zone disposed on the platform or cartridge receiving flow of the lysed-digested-extracted sample from the sample application zone by capillary action, the migration zone including a binding molecule to bind with an analyte of interest to generate an analyte of interest complex,
wherein qualitative detection of the analyte of interest complex in the migration zone indicates presence of the analyte of interest in the lysed-digested-extracted sample and wherein the analyte of interest is a nucleocapsid protein antigen from SARS-CoV-2 and wherein when the digestive enzyme is one or more digestive enzymes in a solution with the detergent, the one or more digestive enzymes being in an amount ranging from about 0.1% to about 10% of total volume of the sample and the one or more detergents being in an amount ranging from about 0.1% to about 2% of total volume of the sample.
2. The disease detection system of claim 1 wherein the sample is from collected sputum, blood, serum, plasma, synovial fluid, lavage fluids, vaginal or urethral secretions, tissue biopsies, cerebrospinal fluid, amniotic fluid, urine, tears, sweat or transdermal exudates skin, nails, feces, hair, or hair follicles and wherein the binding molecule is an antibody, the analyte of interest complex is an antigen-antibody complex.
3. The disease detection system of claim 1 wherein the digestive enzyme is subtilisin.
4. The disease detection system of claim 1 wherein the particle is a bead formed of glass, a polymeric material or a mixture of glass and a polymeric material.
5. A disease detection system, comprising:
a platform or cartridge configured to perform a rapid lateral flow chromatographic immunoassay (LFIA) test;
a container or tube configured for receiving a sample;
a detergent contained in the container or tube, the detergent comprising one or more non-ionic detergents;
a digestive enzyme, the digestive enzyme is in solution with the detergent contained in the container or tube or the digestive enzyme is immobilized on a solid support, the solid support being a surface of a particle within the container or tube or the solid support being an inner surface of the container or tube, the digestive enzyme is one or more of subtilisin, trypsin, pepsin, chymotrypsin, pronase, papain, proteinase K, thermophilic enzyme, hyaluronidase, and amylase;
a sample application zone disposed on or in the platform or cartridge configured for receiving the sample, the sample having been disrupted by the digestive enzyme and the detergent contained in the container or tube to release content and digest proteins and glycoproteins of the sample to form a lysed-digested-extracted sample; and
a migration zone disposed on the platform or cartridge receiving flow of the lysed-digested-extracted sample from the sample application zone by capillary action, the migration zone including a binding molecule to bind with an analyte of interest to generate an analyte of interest complex,
wherein qualitative detection of the analyte of interest complex in the migration zone indicates presence of the analyte of interest in the lysed-digested-extracted sample and wherein the qualitative detection of the analyte of interest complex in the migration zone is measured by formation of a color when the binding molecule conjugated with a color indicator interacts to bind with the analyte of interest and generate a characteristic color and wherein the analyte of interest is a nucleocapsid protein antigen from SARS-CoV-2 and wherein when the digestive enzyme is one or more digestive enzymes in a solution with the detergent, the one or more digestive enzymes being in an amount ranging from about 0.1% to about 10% of total volume of the sample and the one or more detergents being in an amount ranging from about 0.1% to about 2% of total volume of the sample.
6. The disease detection system of claim 1 wherein the qualitative detection of the analyte of interest complex in the migration zone is a colorimetric signal generated when the binding molecule interacts to bind with the analyte of interest, the colorimetric signal being detectable if visible with the naked eye or being measured by a detector and being processed at a central processing unit (CPU) configured to organize and store results and data directed to the colorimetric signal, the central processing unit (CPU) configured to calibrate the data against standards and the central processing unit (CPU) configured to send the data via to a healthcare specialist for interpretation of the data or to a specialized laboratory for performing analysis of the data.
7. A disease detection system, comprising:
a platform or cartridge configured to perform a rapid lateral flow chromatographic immunoassay (LFIA) test;
a container or tube configured for receiving a sample;
a detergent contained in the container or tube, the detergent comprising one or more non-ionic detergents;
a digestive enzyme, the digestive enzyme is in solution with the detergent contained in the container or tube or the digestive enzyme is immobilized on a solid support, the solid support being a surface of a particle within the container or tube or the solid support being an inner surface of the container or tube, the digestive enzyme is one or more of subtilisin, trypsin, pepsin, chymotrypsin, pronase, papain, proteinase K, thermophilic enzyme, hyaluronidase, and amylase;
a sample application zone disposed on or in the platform or cartridge configured for receiving the sample, the sample having been disrupted by the digestive enzyme and the detergent contained in the container or tube to release content and digest proteins and glycoproteins of the sample to form a lysed-digested-extracted sample; and
a migration zone disposed on the platform or cartridge receiving flow of the lysed-digested-extracted sample from the sample application zone by capillary action, the migration zone including a binding molecule to bind with an analyte of interest to generate an analyte of interest complex,
wherein qualitative detection of the analyte of interest complex in the migration zone indicates presence of the analyte of interest in the lysed-digested-extracted sample and wherein the qualitative detection of the analyte of interest complex in the migration zone is measured by using a chromogenic reagent with the binding molecule generating fluorescence, bioluminescence, or chemiluminescence when the binding molecule interacts to bind with the analyte of interest and the fluorescence, bioluminescence, or chemiluminescence is detected with a detector and wherein when the digestive enzyme is one or more digestive enzymes in a solution with the detergent, the one or more digestive enzymes being in an amount ranging from about 0.1% to about 10% of total volume of the sample and the one or more detergents being in an amount ranging from about 0.1% to about 2% of total volume of the sample; and wherein the analyte of interest is a protein.
8. The disease detection system of claim 1 wherein the qualitative detection of the analyte of interest complex in the migration zone is a signal of one or more of a colorimetric signal, fluorescent signal, bioluminescent signal or chemiluminescent signal generated when the binding molecule interacts to bind with the analyte of interest, the signal being detectable if visible with the naked eye or being measured by a detector and information of the qualitative detection and quantitative data being processed at a central processing unit (CPU) configured to organize and store results and data directed to the signal, the central processing unit (CPU) configured to calibrate the data against standards and the central processing unit (CPU) configured to send the data via internet to a healthcare specialist for interpretation of the data or to a specialized laboratory for performing analysis of the data.